Cambridge Epigenetix Licenses Fundamental DNA Methylation IP from Boston Children’s Hospital

Product News   Apr 28, 2017 | Original story from Cambridge Epigenetix

 
Cambridge Epigenetix Licenses Fundamental DNA Methylation IP from Boston Children’s Hospital

Anjana Rao. Credit: Cambridge Epigenetix

 
 
FURTHER INFORMATION
 
 
 

Related Product News

Lipid Analysis for Early Stages of Drug Discovery

Product News

Lipotype performed lipid analysis for Flagship VentureLabs with the aim to better understand molecular compositions of chondrisomes.

READ MORE

Qlucore Launches Omics Explorer 3.3

Product News

Qlucore releases advanced data analysis software to allow researchers to explore Next Generation Sequencing and data.

READ MORE

BD Expands Genomics Portfolio with New Single Cell Platform for RNA Expression Analysis

Product News

BD Rhapsody is a new platform for single cell analysis with the ability to detect rare molecules responsible for biological diversity that are often missed with whole transcriptome profiling.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cancer Research Diagnostics Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE